Pharsight

Janssen Pharms patents expiration

1. Axert patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5565447 JANSSEN PHARMS Indole derivatives
May, 2015

(8 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5565447

(Pediatric)

JANSSEN PHARMS Indole derivatives
Nov, 2015

(8 years ago)

Drugs and Companies using ALMOTRIPTAN MALATE ingredient

Market Authorisation Date: 07 May, 2001

Treatment: Treatment of migraine

Dosage: TABLET;ORAL

How can I launch a generic of AXERT before it's drug patent expiration?
More Information on Dosage

AXERT family patents

Family Patents

2. Concerta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9029416 JANSSEN PHARMS Methods and devices for providing prolonged drug therapy
Jul, 2017

(6 years ago)

US6930129 JANSSEN PHARMS Methods and devices for providing prolonged drug therapy
Jul, 2017

(6 years ago)

US6919373 JANSSEN PHARMS Methods and devices for providing prolonged drug therapy
Jul, 2017

(6 years ago)

US8163798 JANSSEN PHARMS Methods and devices for providing prolonged drug therapy
Jul, 2017

(6 years ago)

US9144549 JANSSEN PHARMS Methods and devices for providing prolonged drug therapy
Jul, 2017

(6 years ago)

US9000038 JANSSEN PHARMS Methods and devices for providing prolonged drug therapy
Jul, 2017

(6 years ago)

US8629179 JANSSEN PHARMS Methods and devices for providing prolonged drug therapy
Jul, 2017

(6 years ago)

US6930129

(Pediatric)

JANSSEN PHARMS Methods and devices for providing prolonged drug therapy
Jan, 2018

(6 years ago)

US6919373

(Pediatric)

JANSSEN PHARMS Methods and devices for providing prolonged drug therapy
Jan, 2018

(6 years ago)

US9000038

(Pediatric)

JANSSEN PHARMS Methods and devices for providing prolonged drug therapy
Jan, 2018

(6 years ago)

US8629179

(Pediatric)

JANSSEN PHARMS Methods and devices for providing prolonged drug therapy
Jan, 2018

(6 years ago)

US8163798

(Pediatric)

JANSSEN PHARMS Methods and devices for providing prolonged drug therapy
Jan, 2018

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-88) Nov 04, 2012

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 01 August, 2000

Treatment: Method of treating adhd; For claims 1-3,6-13,16-24 and 26-32: method of treating adhd; Method of treating adhd in children 6 years of age and older and adolescents

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONCERTA before it's drug patent expiration?
More Information on Dosage

CONCERTA family patents

Family Patents

3. Ditropan Xl patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5840754 JANSSEN PHARMS Dosage form comprising oxybutynin
May, 2015

(8 years ago)

US5912268 JANSSEN PHARMS Dosage form and method for treating incontinence
May, 2015

(8 years ago)

US5674895 JANSSEN PHARMS Dosage form comprising oxybutynin
May, 2015

(8 years ago)

US6262115 JANSSEN PHARMS Method for the management of incontinence
May, 2015

(8 years ago)

US6262115

(Pediatric)

JANSSEN PHARMS Method for the management of incontinence
Nov, 2015

(8 years ago)

US5912268

(Pediatric)

JANSSEN PHARMS Dosage form and method for treating incontinence
Nov, 2015

(8 years ago)

US5840754

(Pediatric)

JANSSEN PHARMS Dosage form comprising oxybutynin
Nov, 2015

(8 years ago)

US5674895

(Pediatric)

JANSSEN PHARMS Dosage form comprising oxybutynin
Nov, 2015

(8 years ago)

Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient

Market Authorisation Date: 16 December, 1998

Treatment: Management of incontinence, mgt of hormone replacement therapy, treatment of involuntary incontinence, mgt overactive bladder and increasing compliance in such pt

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of DITROPAN XL before it's drug patent expiration?
More Information on Dosage

DITROPAN XL family patents

Family Patents

4. Invega Hafyera patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11324751 JANSSEN PHARMS Dosing regimens associated with extended release paliperidone injectable formulations
May, 2041

(17 years from now)

US11304951 JANSSEN PHARMS Dosing regimens associated with extended release paliperidone injectable formulations
May, 2041

(17 years from now)

US11666697 JANSSEN PHARMS Methods for ensuring resuspension of paliperidone palmitate formulations
Nov, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) Aug 30, 2024
New Product(NP) May 18, 2018

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Market Authorisation Date: 30 August, 2021

Treatment: Treatment of schizophrenia by administering a dose up to two weeks before or three weeks after the scheduled six-month dose; Reinitiation of schizophrenia treatment wherein more than 6 months 3 weeks ...

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of INVEGA HAFYERA before it's drug patent expiration?
More Information on Dosage

INVEGA HAFYERA family patents

Family Patents

5. Invega Sustenna patents expiration

INVEGA SUSTENNA's oppositions filed in EPO
INVEGA SUSTENNA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5254556 JANSSEN PHARMS 3-piperidinyl-1,2-benzisoxazoles
Oct, 2013

(10 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5352459 JANSSEN PHARMS Use of purified surface modifiers to prevent particle aggregation during sterilization
Dec, 2012

(11 years ago)

US5352459

(Pediatric)

JANSSEN PHARMS Use of purified surface modifiers to prevent particle aggregation during sterilization
Jun, 2013

(10 years ago)

US5254556

(Pediatric)

JANSSEN PHARMS 3-piperidinyl-1,2-benzisoxazoles
Apr, 2014

(10 years ago)

US6077843 JANSSEN PHARMS Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
May, 2017

(6 years ago)

US6077843

(Pediatric)

JANSSEN PHARMS Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
Nov, 2017

(6 years ago)

US6555544 JANSSEN PHARMS Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters
Nov, 2018

(5 years ago)

US6555544

(Pediatric)

JANSSEN PHARMS Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters
May, 2019

(4 years ago)

US9439906 JANSSEN PHARMS Dosing regimen associated with long acting injectable paliperidone esters
Jan, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 19, 2011
New Indication(I-698) Nov 12, 2017
M(M-215) Dec 20, 2020
New Dosage Form(NDF) Jul 31, 2012
Pediatric Exclusivity(PED) Jan 31, 2013
M(M-119) Aug 29, 2015

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

NCE-1 date: 01 February, 2012

Market Authorisation Date: 31 July, 2009

Treatment: Treatment of schizophrenia; Dosing regimen for the treatment of schizophrenia in adults by administering two loading doses of paliperidone palmitate followed by maintenance dose(s)

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of INVEGA SUSTENNA before it's drug patent expiration?
More Information on Dosage

INVEGA SUSTENNA family patents

Family Patents

6. Invega Trinza patents expiration

INVEGA TRINZA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6077843 JANSSEN PHARMS Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
May, 2017

(6 years ago)

US6077843

(Pediatric)

JANSSEN PHARMS Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
Nov, 2017

(6 years ago)

US10143693 JANSSEN PHARMS Dosing regimen for missed doses for long-acting injectable paliperidone esters
Apr, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) Aug 30, 2024
New Product(NP) May 18, 2018

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Market Authorisation Date: 30 August, 2021

Treatment: Treatment of schizophrenia; Reinitiation of schizophrenia treatment following a missed dose more than 9 months ago

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of INVEGA TRINZA before it's drug patent expiration?
More Information on Dosage

INVEGA TRINZA family patents

Family Patents

7. Invokamet patents expiration

INVOKAMET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(3 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(3 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403 JANSSEN PHARMS Glucopyranoside compound
Jul, 2024

(3 months from now)

US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(11 months from now)

US11576894 JANSSEN PHARMS Combination therapy for the treatment of diabetes
Jul, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 29, 2018
New Indication(I-735) May 20, 2019
New Combination(NC) Aug 08, 2017
M(M-197) Feb 01, 2020
New Indication(I-788) Oct 29, 2021

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 29 March, 2017

Market Authorisation Date: 08 August, 2014

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascu...

Dosage: TABLET;ORAL

How can I launch a generic of INVOKAMET before it's drug patent expiration?
More Information on Dosage

INVOKAMET family patents

Family Patents

8. Invokamet Xr patents expiration

INVOKAMET XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(3 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(3 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6723340 JANSSEN PHARMS Optimal polymer mixtures for gastric retentive tablets
Oct, 2021

(2 years ago)

US8785403 JANSSEN PHARMS Glucopyranoside compound
Jul, 2024

(3 months from now)

US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(11 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Aug 08, 2017
New Indication(I-735) May 20, 2019
New Chemical Entity Exclusivity(NCE) Mar 29, 2018
New Indication(I-788) Oct 29, 2021

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 29 March, 2017

Market Authorisation Date: 20 September, 2016

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascu...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of INVOKAMET XR before it's drug patent expiration?
More Information on Dosage

INVOKAMET XR family patents

Family Patents

9. Invokana patents expiration

INVOKANA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(3 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(3 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(11 months from now)

US10617668 JANSSEN PHARMS Pharmaceutical formulations
May, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-809) Sep 27, 2022
New Indication(I-733) May 20, 2019
M(M-197) Feb 01, 2020
New Indication(I-788) Oct 29, 2021
New Chemical Entity Exclusivity(NCE) Mar 29, 2018

Drugs and Companies using CANAGLIFLOZIN ingredient

NCE-1 date: 29 March, 2017

Market Authorisation Date: 29 March, 2013

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diab...

Dosage: TABLET;ORAL

How can I launch a generic of INVOKANA before it's drug patent expiration?
More Information on Dosage

INVOKANA family patents

Family Patents

10. Levaquin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6806256 JANSSEN PHARMS Taste masked liquid pharmaceutical compositions
Feb, 2022

(2 years ago)

US6806256

(Pediatric)

JANSSEN PHARMS Taste masked liquid pharmaceutical compositions
Aug, 2022

(1 year, 7 months ago)

Drugs and Companies using LEVOFLOXACIN ingredient

Market Authorisation Date: 21 October, 2004

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of LEVAQUIN before it's drug patent expiration?
More Information on Dosage

LEVAQUIN family patents

Family Patents

11. Ortho Evra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5972377 JANSSEN PHARMS Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
Jun, 2015

(8 years ago)

US5876746 JANSSEN PHARMS Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
Nov, 2015

(8 years ago)

Drugs and Companies using ETHINYL ESTRADIOL; NORELGESTROMIN ingredient

Market Authorisation Date: 20 November, 2001

Treatment: Prevention of ovulation in a woman

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

How can I launch a generic of ORTHO EVRA before it's drug patent expiration?
More Information on Dosage

ORTHO EVRA family patents

Family Patents

12. Ortho Tri-cyclen Lo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6214815 JANSSEN PHARMS Triphasic oral contraceptive
Jun, 2019

(4 years ago)

US6214815

(Pediatric)

JANSSEN PHARMS Triphasic oral contraceptive
Dec, 2019

(4 years ago)

Drugs and Companies using ETHINYL ESTRADIOL; NORGESTIMATE ingredient

Market Authorisation Date: 22 August, 2002

Treatment: Contraception

Dosage: TABLET;ORAL-28

How can I launch a generic of ORTHO TRI-CYCLEN LO before it's drug patent expiration?
More Information on Dosage

ORTHO TRI-CYCLEN LO family patents

Family Patents

13. Ponvory patents expiration

PONVORY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE43728 JANSSEN PHARMS Thiazolidin-4-one derivatives
Nov, 2024

(6 months from now)

US9062014 JANSSEN PHARMS Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one
May, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000018 JANSSEN PHARMS Thiazolidin-4-one-derivatives
Nov, 2024

(6 months from now)

US8273779 JANSSEN PHARMS Thiazolidin 4-one derivatives
Dec, 2025

(1 year, 7 months from now)

US10220023 JANSSEN PHARMS Dosing regimen for a selective S1P1 receptor agonist
Dec, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 18, 2026

Drugs and Companies using PONESIMOD ingredient

NCE-1 date: 18 March, 2025

Market Authorisation Date: 18 March, 2021

Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive dise...

Dosage: TABLET;ORAL

More Information on Dosage

PONVORY family patents

Family Patents

14. Razadyne patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6099863 JANSSEN PHARMS Fast-dissolving galanthamine hydrobromide tablet
Jun, 2017

(6 years ago)

US6358527 JANSSEN PHARMS Fast-dissolving galanthamine hydrobromide tablet
Jun, 2017

(6 years ago)

Drugs and Companies using GALANTAMINE HYDROBROMIDE ingredient

Market Authorisation Date: 28 February, 2001

Treatment: Treatment of alzheimer's dementia

Dosage: TABLET;ORAL

How can I launch a generic of RAZADYNE before it's drug patent expiration?
More Information on Dosage

RAZADYNE family patents

Family Patents

15. Razadyne Er patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7160559 JANSSEN PHARMS Controlled release galantamine composition
Dec, 2019

(4 years ago)

Drugs and Companies using GALANTAMINE HYDROBROMIDE ingredient

Market Authorisation Date: 01 April, 2005

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of RAZADYNE ER before it's drug patent expiration?
More Information on Dosage

RAZADYNE ER family patents

Family Patents

16. Risperdal patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5453425 JANSSEN PHARMS Risperidone oral formulation
Jul, 2014

(9 years ago)

USRE39181 JANSSEN PHARMS Aqueous risperidone formulations
Jul, 2014

(9 years ago)

US5648093 JANSSEN PHARMS Pharmaceutical and other dosage forms
Jul, 2014

(9 years ago)

USRE39181

(Pediatric)

JANSSEN PHARMS Aqueous risperidone formulations
Jan, 2015

(9 years ago)

US5453425

(Pediatric)

JANSSEN PHARMS Risperidone oral formulation
Jan, 2015

(9 years ago)

US5648093

(Pediatric)

JANSSEN PHARMS Pharmaceutical and other dosage forms
Jan, 2015

(9 years ago)

US6224905 JANSSEN PHARMS Biconvex rapidly disintegrating dosage forms
Jun, 2017

(6 years ago)

US6224905

(Pediatric)

JANSSEN PHARMS Biconvex rapidly disintegrating dosage forms
Dec, 2017

(6 years ago)

Drugs and Companies using RISPERIDONE ingredient

Market Authorisation Date: 10 June, 1996

Treatment: NA

Dosage: SOLUTION;ORAL; TABLET, ORALLY DISINTEGRATING;ORAL

How can I launch a generic of RISPERDAL before it's drug patent expiration?
More Information on Dosage

RISPERDAL family patents

Family Patents

17. Risperdal Consta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7547452 JANSSEN PHARMS Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
Nov, 2013

(10 years ago)

US6368632 JANSSEN PHARMS Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
Nov, 2013

(10 years ago)

US5965168 JANSSEN PHARMS Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
Nov, 2013

(10 years ago)

US6110921 JANSSEN PHARMS Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
Nov, 2013

(10 years ago)

US6110921

(Pediatric)

JANSSEN PHARMS Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
May, 2014

(9 years ago)

US7547452

(Pediatric)

JANSSEN PHARMS Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
May, 2014

(9 years ago)

US5965168

(Pediatric)

JANSSEN PHARMS Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
May, 2014

(9 years ago)

US6368632

(Pediatric)

JANSSEN PHARMS Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
May, 2014

(9 years ago)

US5688801 JANSSEN PHARMS Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
Nov, 2014

(9 years ago)

US5688801

(Pediatric)

JANSSEN PHARMS Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
May, 2015

(8 years ago)

US5916598 JANSSEN PHARMS Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
May, 2017

(6 years ago)

US5792477 JANSSEN PHARMS Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
May, 2017

(6 years ago)

US6403114 JANSSEN PHARMS Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
May, 2017

(6 years ago)

US5916598

(Pediatric)

JANSSEN PHARMS Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
Nov, 2017

(6 years ago)

US5792477

(Pediatric)

JANSSEN PHARMS Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
Nov, 2017

(6 years ago)

US6403114

(Pediatric)

JANSSEN PHARMS Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
Nov, 2017

(6 years ago)

US6194006 JANSSEN PHARMS Preparation of microparticles having a selected release profile
Dec, 2018

(5 years ago)

US6596316 JANSSEN PHARMS Preparation of microparticles having a selected release profile
Dec, 2018

(5 years ago)

US6379703 JANSSEN PHARMS Preparation of microparticles having a selected release profile
Dec, 2018

(5 years ago)

US6194006

(Pediatric)

JANSSEN PHARMS Preparation of microparticles having a selected release profile
Jun, 2019

(4 years ago)

US6596316

(Pediatric)

JANSSEN PHARMS Preparation of microparticles having a selected release profile
Jun, 2019

(4 years ago)

US6379703

(Pediatric)

JANSSEN PHARMS Preparation of microparticles having a selected release profile
Jun, 2019

(4 years ago)

US6667061 JANSSEN PHARMS Preparation of injectable suspensions having improved injectability
May, 2020

(3 years ago)

US6667061

(Pediatric)

JANSSEN PHARMS Preparation of injectable suspensions having improved injectability
Nov, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-597) May 15, 2012
New Indication(I-596) May 15, 2012

Drugs and Companies using RISPERIDONE ingredient

Market Authorisation Date: 12 April, 2007

Treatment: Treatment of schizophrenia; Monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar i disorder

Dosage: INJECTABLE;INTRAMUSCULAR

More Information on Dosage

RISPERDAL CONSTA family patents

Family Patents

18. Sporanox patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5633015 JANSSEN PHARMS Beads having a core coated with an antifungal and a polymer
May, 2014

(9 years ago)

US5707975 JANSSEN PHARMS Oral formulations on an antifungal
Jan, 2015

(9 years ago)

US6407079 JANSSEN PHARMS Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
Jun, 2019

(4 years ago)

Drugs and Companies using ITRACONAZOLE ingredient

Market Authorisation Date: 11 September, 1992

Treatment: NA

Dosage: CAPSULE;ORAL; INJECTABLE;INJECTION

How can I launch a generic of SPORANOX before it's drug patent expiration?
More Information on Dosage

SPORANOX family patents

Family Patents

19. Spravato patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592207 JANSSEN PHARMS Intranasal administration of ketamine to treat depression
Mar, 2027

(2 years from now)

US8785500 JANSSEN PHARMS Intranasal administration of ketamine to treat depression
Mar, 2033

(8 years from now)

US11446260 JANSSEN PHARMS Pharmaceutical composition of S-ketamine hydrochloride
Mar, 2034

(9 years from now)

US10869844 JANSSEN PHARMS Methods for the treatment of depression
Sep, 2035

(11 years from now)

US11311500 JANSSEN PHARMS Methods for the treatment of depression
Sep, 2035

(11 years from now)

US11173134 JANSSEN PHARMS Methods for the treatment of depression
Sep, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
NCE*(NCE*) Mar 05, 2024
New Indication(I-840) Jul 31, 2023

Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 March, 2019

Treatment: Treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant; Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketami...

Dosage: SPRAY;NASAL

How can I launch a generic of SPRAVATO before it's drug patent expiration?
More Information on Dosage

SPRAVATO family patents

Family Patents

20. Topamax patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6503884 JANSSEN PHARMS Migraine treatment method using topiramate and related compounds
Oct, 2015

(8 years ago)

US7018983 JANSSEN PHARMS Treatment of migraine
Oct, 2015

(8 years ago)

US7498311 JANSSEN PHARMS Treatment of migraine
Oct, 2015

(8 years ago)

US5998380 JANSSEN PHARMS Treatment of migraine
Oct, 2015

(8 years ago)

US6503884

(Pediatric)

JANSSEN PHARMS Migraine treatment method using topiramate and related compounds
Apr, 2016

(8 years ago)

US5998380

(Pediatric)

JANSSEN PHARMS Treatment of migraine
Apr, 2016

(8 years ago)

US7498311

(Pediatric)

JANSSEN PHARMS Treatment of migraine
Apr, 2016

(8 years ago)

US7018983

(Pediatric)

JANSSEN PHARMS Treatment of migraine
Apr, 2016

(8 years ago)

US7125560 JANSSEN PHARMS Pharmaceutical composition of topiramate
Mar, 2019

(5 years ago)

US7125560

(Pediatric)

JANSSEN PHARMS Pharmaceutical composition of topiramate
Sep, 2019

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 15, 2014
Pediatric Exclusivity(PED) Jun 22, 2013
M(M-54) Dec 22, 2012

Drugs and Companies using TOPIRAMATE ingredient

Market Authorisation Date: 24 December, 1996

Treatment: Prophylactic treatment of migraine; Treatment of seizures

Dosage: TABLET;ORAL; CAPSULE;ORAL

How can I launch a generic of TOPAMAX before it's drug patent expiration?
More Information on Dosage

TOPAMAX family patents

Family Patents

21. Topamax Sprinkle patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5998380 JANSSEN PHARMS Treatment of migraine
Oct, 2015

(8 years ago)

US6503884 JANSSEN PHARMS Migraine treatment method using topiramate and related compounds
Oct, 2015

(8 years ago)

US7018983 JANSSEN PHARMS Treatment of migraine
Oct, 2015

(8 years ago)

US7498311 JANSSEN PHARMS Treatment of migraine
Oct, 2015

(8 years ago)

US5998380

(Pediatric)

JANSSEN PHARMS Treatment of migraine
Apr, 2016

(8 years ago)

US6503884

(Pediatric)

JANSSEN PHARMS Migraine treatment method using topiramate and related compounds
Apr, 2016

(8 years ago)

US7018983

(Pediatric)

JANSSEN PHARMS Treatment of migraine
Apr, 2016

(8 years ago)

US7498311

(Pediatric)

JANSSEN PHARMS Treatment of migraine
Apr, 2016

(8 years ago)

US7125560 JANSSEN PHARMS Pharmaceutical composition of topiramate
Mar, 2019

(5 years ago)

US7125560

(Pediatric)

JANSSEN PHARMS Pharmaceutical composition of topiramate
Sep, 2019

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 15, 2014
Pediatric Exclusivity(PED) Jun 22, 2013
M(M-54) Dec 22, 2012

Drugs and Companies using TOPIRAMATE ingredient

Market Authorisation Date: 26 October, 1998

Treatment: Prophylactic treatment of migraine; Treatment of seizures

Dosage: CAPSULE;ORAL

How can I launch a generic of TOPAMAX SPRINKLE before it's drug patent expiration?
More Information on Dosage

TOPAMAX SPRINKLE family patents

Family Patents

22. Ultram patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6339105 JANSSEN PHARMS Analgesic regimen
Oct, 2019

(4 years ago)

US6339105

(Pediatric)

JANSSEN PHARMS Analgesic regimen
Apr, 2020

(4 years ago)

Drugs and Companies using TRAMADOL HYDROCHLORIDE ingredient

Market Authorisation Date: 03 March, 1995

Treatment: A titration dosing regimen for the treatment of pain using an initial dose of about 25mg

Dosage: TABLET;ORAL

How can I launch a generic of ULTRAM before it's drug patent expiration?
More Information on Dosage

ULTRAM family patents

Family Patents

23. Xarelto patents expiration

XARELTO's oppositions filed in EPO
XARELTO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7585860 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Dec, 2020

(3 years ago)

US7157456 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Aug, 2024

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7592339 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Dec, 2020

(3 years ago)

US9415053 JANSSEN PHARMS Solid, orally administrable pharmaceutical composition
Nov, 2024

(6 months from now)

US7157456

(Pediatric)

JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Feb, 2025

(10 months from now)

US9415053

(Pediatric)

JANSSEN PHARMS Solid, orally administrable pharmaceutical composition
May, 2025

(1 year, 22 days from now)

US9539218 JANSSEN PHARMS Prevention and treatment of thromboembolic disorders
Feb, 2034

(9 years from now)

US9539218

(Pediatric)

JANSSEN PHARMS Prevention and treatment of thromboembolic disorders
Aug, 2034

(10 years from now)

US10828310 JANSSEN PHARMS Reducing the risk of cardiovascular events
Jan, 2039

(14 years from now)

US10828310

(Pediatric)

JANSSEN PHARMS Reducing the risk of cardiovascular events
Jul, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-867) Aug 23, 2024
Pediatric Exclusivity(PED) Feb 23, 2025
New Indication(I-824) Oct 11, 2021
New Dosing Schedule(D-168) Oct 27, 2020
New Indication(I-810) Oct 11, 2022
M(M-284) Mar 10, 2023
New Indication(I-660) Nov 02, 2015
New Indication(I-661) Nov 02, 2015
New Indication(I-662) Nov 02, 2015
New Chemical Entity Exclusivity(NCE) Jul 01, 2016
New Indication(I-643) Nov 04, 2014

Drugs and Companies using RIVAROXABAN ingredient

NCE-1 date: 24 February, 2024

Market Authorisation Date: 11 October, 2018

Treatment: Reduction of risk of major cardiovascular events (cv death, mi, and stroke) in chronic cad or pad; Treatment of venous thromboembolism (vte) and the reduction in the risk of recurrent vte in pediatric...

Dosage: TABLET;ORAL; FOR SUSPENSION;ORAL

How can I launch a generic of XARELTO before it's drug patent expiration?
More Information on Dosage

XARELTO family patents

Family Patents